TissueTech’s initial research and development efforts were focused on the development of its cornerstone cryopreservation technology – CRYOTEK. The CRYOTEK process is a proprietary tissue-processing method that preserves the innate biological and structural integrity of the natural placental tissue and therefore preserves and delivers the anti-inflammatory, anti-scarring, and anti-angiogenesis properties of that matrix. In particular, the CRYOTEK process is the ONLY method proven to effectively retain the Heavy Chain Hyaluronic Acid/Pentraxin3 (HC-HA/PTX3) complex, which has been demonstrated to orchestrate an environment that promotes regenerative healing. CRYOTEK-processed tissues are also the only available placental allografts that have been shown to be equivalent to fresh placental tissue and superior to other available placental allografts that are provided in a dehydrated state.
The clinical benefits of the CRYOTEK process have been demonstrated in more than 300 peer-reviewed publications. By devitalizing the resident living cells, CRYOTEK minimizes the risk of an immune reaction while preserving key components of the extracellular matrix: 1,2,3
Cryopreserved umbilical cord and amniotic membrane have been demonstrated to promote critical healing actions:
Consistent with our mission of continued innovation, TissueTech more recently commercialized allografts preserved via our proprietary SteriTek preservation process. This unique technology yields a shelf-stable product while maintaining the natural hydration of the tissue. The tissue is cleaned, processed and packaged consistent with the CRYOTEK cryopreservation process to maintain the structural and biological integrity of the natural tissue, but is then terminally sterilized using gamma irradiation, yielding a fully hydrated product that can be stored at controlled room temperature.
The Star, Christchurch NZ Issue 8668 7 July 1906
Somasundaram K et al. J Pathol (1970) 100:81-86.
Rowlatt U. Virchows Arch. (1979)381: 353-361.